Pharma two b and hepion pharmaceuticals, inc. announce filing of registration statement on form f-4 related to proposed merger

Kiryat ono, israel and edison, n.j., sept. 04, 2024 (globe newswire) -- pharma two b ltd. (“pharma two b”), a late-clinical stage company that is developing p2b001, an innovative combination product candidate for the treatment of parkinson's disease (“pd”) and hepion pharmaceuticals, inc. (nasdaq: hepa) (“hepion”), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today jointly announced the filing of a registration statement of pharma two b on form f-4 (the "registration statement") with the u.s. securities and exchange commission (the “sec”).
HEPA Ratings Summary
HEPA Quant Ranking